Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Overview of reported late toxicities in EBRT for localized prostate cancer

From: Three-dimensional conformal arc radiotherapy using a C-arm linear accelerator with a computed tomography on-rail system for prostate cancer: clinical outcomes

Study (reference) Patients Prescription dose Technique Posterior margin (other) GI toxicity (%) GU toxicity (%) Grading scale Follow-up
  (n) (Gy)   (cm) Grade 2 Grade 3 Grade 2 Grade 3   (months)
Present study 261 78–86 3D-CRT 0.5 (0.5) 1.9 0.4 10.3 1.1 CTCAE4.0 61
RTOG9406 (8) 167 79.2 3D-CRT 0.5–1.0 11–14, Grade 2/3 18–21, Grade 2/3 RTOG 102–110
  220 78    25–26   23–28    71–73
Ikeda et al. [24] 150 74 3D-CRT 0.6 (0.9) 5.5, Grade 2/3 2.9, Grade 2/3 RTOG/EORTC 89
Kuban et al. [12] 151 78 3D-CRT - (box four field) 19 7 7 3 RTOG/LENT 61
Spratt et al. [20] 1002 86.4 IMRT 0.6 (1.0) 4.4, Grade 2/3 21.1, Grade 2/3 CTCAE4.0 63
Eade et al. [21] 216 74–78 IMRT 0.5–0.6 (0.8) 2.4 0 3 0.5 RTOG 48
De Meerleer et al. [22] 133 74–76 IMRT 0.7 (1.0) 17 1 19 3 RTOG 36
  1. EBRT external beam radiotherapy, 3D-CRT three-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy, RTOG radiation therapy oncology group, LENT late effects normal tissue task force, CTCAE common terminology criteria for adverse events